News | September 18, 2024
Lupin inks licensing agreement with Takeda to commercialize Vonoprazan
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) is indicated to relieve redness of the eye due to minor eye irritations.
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
